Need Assistance?

US & Canada:
+
UK: +

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

5-Aminovaleric acid

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

5-Aminovaleric acid is used in the study of metabolic changes in male germ cells (toxins) after 24 hours of extinguishing cigarette smokes. Also used in the comprehensive characterization of the human saliva metabolome and in identification of different metabolites like sphingomyelins, phosphatidyl cholines, vitamins and trace elements in human saliva which showed diurnal variation.

Category

Other Unnatural Amino Acids

Catalog number

BAT-007881

CAS number

660-88-8

Molecular Formula

C5H11NO2

Molecular Weight

117.15

Specification
Reference Reading

IUPAC Name

5-aminopentanoic acid

Synonyms

5-Ava-OH; 5-Amino-n-pentanoic acid; 5-Aminopentanoic acid; H-5-Ava-OH; delta-Aminovaleric acid; Homopiperidinic acid; 5-amino-pentanoic acid; Pentanoic acid, 5-amino-; Valeric acid, 5-amino-; delta-Amino-n-valeric acid; 5-aminopentanoate; 5-aminovalerate; 5-ammoniopentanoate; H 5 Ava OH

Related CAS

627-95-2 (hydrochloride)

Appearance

White to yellow to brown powder

Purity

≥ 98% (HPLC)

Density

1.200 g/cm3 (Predicted)

Melting Point

158-161 °C

Boiling Point

247.5±23.0 °C (Predicted)

Storage

Store at RT

InChI

InChI=1S/C5H11NO2/c6-4-2-1-3-5(7)8/h1-4,6H2,(H,7,8)

InChI Key

JJMDCOVWQOJGCB-UHFFFAOYSA-N

Canonical SMILES

C(CCN)CC(=O)O

1.5-aminovaleric acid suppresses the development of severe seizures in the methionine sulfoximine model of mesial temporal lobe epilepsy.

Dhaher R1, Damisah EC2, Wang H1, Gruenbaum SE1, Ong C1, Zaveri HP3, Gruenbaum BF1, Eid T4. Neurobiol Dis. 2014 Jul;67:18-23. doi: 10.1016/j.nbd.2014.03.006. Epub 2014 Mar 14.

Mesial temporal lobe epilepsy (MTLE) is one of the most common forms of drug-resistant, localization-related epilepsies in humans. One potential therapeutic target is the brain glutamine-glutamate-GABA metabolic pathway, which is perturbed in patients with MTLE. Loss of glutamine synthetase (GS) in astrocytes may be critically involved in this perturbation, which can be modeled by infusing the GS inhibitor methionine sulfoximine (MSO) into the entorhinal-hippocampal area in rats. Because 5-aminovaleric acid (5-AV) has been implicated in modulation of the glutamine-glutamate-GABA metabolic pathway, we hypothesized that 5-AV would alter the expression of seizures in the MSO model of MTLE. Male Sprague Dawley rats (300-330g) were implanted with an Alzet pump placed subcutaneously in the abdominal region to release either 5-AV (0.05mg/mL, n=6) or phosphate buffered saline (PBS, n=6) at a rate of 2.5μl/h over 28days. Five to 7days after surgery, all rats were implanted with an intracranial pump infusing MSO (2.